A61K31/185

Methods for treating thrombocytopenia

The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

Methods for treating thrombocytopenia

The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.

ANTIBODY THAT BINDS ERBB-2 AND ERBB-3

The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.

ANTIBODY THAT BINDS ERBB-2 AND ERBB-3

The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.

Compositions and Methods for Treatment of Prediabetes
20170312329 · 2017-11-02 ·

The invention provides compositions and methods to treat prediabetes. In particular, the inventor has discovered that particular combinations of diverse types of antioxidants have synergistic and surprising effects for use against prediabetes. The composition includes: a plurality of heteroatom-based antioxidants having the formula X—CH.sub.2—CH(R)—(CH.sub.2).sub.m—Z; a plurality of antioxidants with a conjugated segment; an antioxidant that is a flavan-3-ol; and an antioxidant that contains a disulfide bond. The antioxidants are chosen such that at least one has a pro-oxidative effect.

Compositions and Methods for Treatment of Prediabetes
20170312329 · 2017-11-02 ·

The invention provides compositions and methods to treat prediabetes. In particular, the inventor has discovered that particular combinations of diverse types of antioxidants have synergistic and surprising effects for use against prediabetes. The composition includes: a plurality of heteroatom-based antioxidants having the formula X—CH.sub.2—CH(R)—(CH.sub.2).sub.m—Z; a plurality of antioxidants with a conjugated segment; an antioxidant that is a flavan-3-ol; and an antioxidant that contains a disulfide bond. The antioxidants are chosen such that at least one has a pro-oxidative effect.

Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts

Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5 2,5-dihydroxybenzenesulfonic acid are provided. ##STR00001##

Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts

Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5 2,5-dihydroxybenzenesulfonic acid are provided. ##STR00001##

Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
09801816 · 2017-10-31 · ·

Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
09801816 · 2017-10-31 · ·

Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.